TY - GEN
T1 - Genomic analysis ofMycobacterium brumaesustains its nonpathogenic and immunogenic phenotype
AU - Renau-Mínguez, Chantal
AU - Herrero-Abadía, Paula
AU - Sentandreu, Vicente
AU - Ruiz-Rodriguez, Paula
AU - Torrents, Eduard
AU - Chiner-Oms, Álvaro
AU - Torres-Puente, Manuela
AU - Comas, Iñaki
AU - Julián, Esther
AU - Coscolla, Mireia
N1 - This research was funded by the Spanish Ministry of Science, Innovation and Universities (MICIN) and co-funded by the FEDER Funds (RTI2018-098777-B-I00, RTI2018-098573-B-100, and RTI2018-094399-A-I00, PID2021-123443OB-I00), the AGAUR-Generalitat of Catalunya (2017SGR-229 and 2017SGR-1079), Ramón y Cajal fellowship (RYC-2015-18213 MICIN), FPI fellowship (PRE-2019-088141 MICIN), Generalitat Valenciana (SEJI/2019/011), MycoNET (RED2018-102677-T), and the European Comission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Program (PTI+ Salud Global).
PY - 2022/12/2
Y1 - 2022/12/2
N2 - M. brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. M. brumae is not pathogenic and its in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. M. brumae genome is composed of a circular chromosome with a high GC content of 69.2 % and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. M. brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae is considerably lower than those of M. bovis BCG. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.
AB - M. brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. M. brumae is not pathogenic and its in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. M. brumae genome is composed of a circular chromosome with a high GC content of 69.2 % and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. M. brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae is considerably lower than those of M. bovis BCG. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.
U2 - 10.1101/2022.12.01.518671
DO - 10.1101/2022.12.01.518671
M3 - Other contribution
ER -